Physician profile
Syed Sayeeduddin
NPI 1467717561
$65,081.53
in general payments reported to CMS, 2019-2025
14 companies · $37K in 2025
The $37K reported for 2025 was more than what 98% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $327 · 2021: $972 · 2022: $2,045 · 2023: $13K · 2024: $11K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $7,054 · Travel and Lodging: $5,296 · Consulting Fee: $150 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,575.00 |
| Food and Beverage | $7,053.75 |
| Travel and Lodging | $5,295.67 |
| Consulting Fee | $150.00 |
| Education | $112.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $59,402.15 | 2019-2025 | |
| Harmony Biosciences LLC | $2,416.18 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $1,604.42 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $602.17 | 2022-2025 | Sunosi |
| Inspire Medical Systems, INC. | $392.13 | 2020-2023 | Inspire |
| Azurity Pharmaceuticals, INC. | $245.58 | 2023-2025 | Horizant, Horizant |
| Lilly USA, LLC | $122.36 | 2025 | Zepbound |
| Eisai INC. | $69.77 | 2020-2022 | |
| Fisher & Paykel Healthcare INC | $55.84 | 2024 | Fisher & Paykel Healthcare |
| Arbor Pharmaceuticals, INC. | $51.43 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $41.92 | 2022-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $38.95 | 2022 | |
| Zoll Respicardia, INC. | $23.09 | 2025 | Remede System |
| Galderma Laboratories, L.P. | $15.54 | 2024 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Sayeeduddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.